TLC-2716, a Potent, Liver-Targeted, Inverse Agonist of the Liver X Receptor (LXR), Demonstrates Profound Reductions in Hepatic and Plasma Lipids in Dysmetabolic Rodent Models (AASLD 2022, Poster #2532)
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
